Munich, Germany

Gerald Beste

USPTO Granted Patents = 4 


Average Co-Inventor Count = 4.0

ph-index = 4

Forward Citations = 130(Granted Patents)


Company Filing History:


Years Active: 2007-2013

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Gerald Beste: Innovator in Anticalin Technology

Introduction: Gerald Beste is a pioneering inventor based in Munich, Germany, known for his significant contributions to the field of biotechnology. With a total of four patents to his name, he plays a crucial role in advancing innovative protein engineering solutions.

Latest Patents: One of Beste's latest inventions revolves around Anticalins, which are novel proteins designed to exhibit binding activities for specific ligands. This groundbreaking invention involves modifying the structure of peptides from the lipocalin family through amino acid replacements in their natural ligand binding pockets, utilizing advanced genetic engineering techniques. These anticalins function similarly to immunoglobulins, enabling the identification and binding of various molecular structures, making them integral to various applications in biotechnology and drug development.

Career Highlights: Gerald Beste's career is marked by his association with Pieris AG, a company at the forefront of biopharmaceutical innovations. His work has established him as a key figure in protein engineering, allowing for the creation of more efficient and targeted therapeutic solutions.

Collaborations: Throughout his career, Beste has collaborated with esteemed colleagues, including Thomas Stibora and Frank Schmidt. Together, they contribute to advancing research and development in the field, further enhancing the potential of their innovations.

Conclusion: Gerald Beste's ingenuity in the realm of anticalin technology showcases the power of innovative thinking in the biotechnology industry. His ongoing contributions at Pieris AG not only exemplify his dedication to scientific advancement but also pave the way for future breakthroughs in the development of therapeutic proteins.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…